Business

ProAxsis Showcases ProteaseTag® Research at NACFC

ProAxsis Showcases ProteaseTag® Research at NACFC.

articleEmv Capital PlcOctober 30, 20174/company/emv-capital-plc/news/proaxsis-showcases-proteasetagr-research-at-nacfc
ProAxsis Showcases ProteaseTag® Research at NACFC

About this update from Emv Capital Plc

[{"type":"text","content":"\n \nRNS Number : 9026U NetScientific PLC 30 October 2017  \n\n \nNetScientific plc\n(\"NetScientific\" or the \"Company\" or the \"Group\")\n \nProAxsis to Showcase ProteaseTag® abstracts at 2017 North American Cystic Fibrosis Conference\n \nLondon, UK - October 30th 2017 - NetScientific plc (\"NetScientific\", AIM:NSCI), the transatlantic healthcare IP commercialisation group, notes the announcement by portfolio company ProAxsis, that it will be presenting further data on its ProteaseTag® technology in two poster sessions at the North American Cystic Fibrosis Conference, which takes place between November 1st - 5th in Indianapolis. The first paper, concerning sputum storage, enables an increase in flexibility for transporting patient samples from trial site to lab. The second paper, which analyses exhaled breath condensate, increases the range of potential research applications for ProAxsis' CE marked NE Immunoassay. Both papers facilitate a greater scope of research applications for ProAxsis' NE Immunoassay. \nCommenting on the news, Francois Martelet, Chief Executive Officer of NetScientific and Chairman of ProAxsis, said: \"We are delighted that ProAxsis' ProteaseTag® technology is increasingly utilised in high-impact respiratory health research, indicating its potential to become a leader in the field. The findings presented at the highly regarded NACF Conference, demonstrate the clinical relevance of ProAxsis technology in cystic fibrosis and will support its move into its commercialisation phase.\" \n \nNetScientific holds a 57% stake on a fully diluted basis in ProAxsis.\n \nThe full text of the announcement from ProAxsis can be found below.\n \n \n#  #  #\n \nFor more information, please contact:\n \n\n\n\n\n  NetScientific\n  François R. Martelet, M.D., CEO\n  Ian Postlethwaite, CFO\n\n\nTel: +44 (0)20 3514 1800\n\n\n\n\n \n  Consilium Strategic Communications\n  Mary-Jane Elliott / Jessica Hodgson /\n  Chris Welsh / Laura Thornton  \n \n\n\n \nTel: +44 (0)20 3709 5700\[email protected]\n\n\n\n\nStifel Nicolaus Europe Limited (NOMAD and Broker)\nJonathan Senior / David Arch / Ben Maddison\n\n\n Tel: +44 (0) 20 7710 7600\n\n\n\n\n \n \nProAxsis to Showcase ProteaseTag® abstr...

More updates from Emv Capital Plc